Skip to main content

Table 1 Baseline demographics and characteristics of the study population

From: Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study

Characteristics and clinical outcomes Total (n = 351) MACE (n = 101) No-MACE (n = 250) P value Bleeding (n = 18) No-bleeding (n = 333) P value
Male sex, n (%) 278 (79.2) 82 (81.2) 196 (78.4) 0.56 13 (72.2) 265 (79.6) 0.454
Age(years, mean ± SD) 58.2 ± 9.0 58.2 ± 8.5 58.3 ± 9.3 0.935 58.0 ± 8.6 58.2 ± 9.1 0.912
BMI (kg/m2, mean ± SD) 28.3 ± 3.8 28.7 ± 3.4 28.4 ± 5.3 0.649 26.8 ± 3.7 28.3 ± 3.8 0.094
Alcohol intake, n (%) 65 (18.5) 14 (13.9) 51 (20.4) 0.153 2 (11.1) 63 (18.9) 0.544
Smoking, n (%) 141 (40.2) 33 (32.7) 108 (43.2) 0.069 6 (33.3) 135 (40.5) 0.544
SBP (mmHg, mean ± SD) 133.3 ± 21.7 134.3 ± 22.2 132.9 ± 21.5 0.575 129.3 ± 19.4 135.5 ± 22.3 0.136
DBP (mmHg, mean ± SD) 80.2 ± 13.4 80.2 ± 13.9 80.3 ± 12.3 0.772 80.7 ± 16.0 80.2 ± 13.3 0.668
TG (mg/dL) 1.67 ± 0.70 1.72 ± 0.77 1.55 ± 0.48 0.148 1.46 ± 0.39 1.68 ± 0.71 0.375
LDL-C (mg/dL) 2.52 ± 0.89 2.41 ± 0.89 2.57 ± 0.57 0.126 2.54 ± 0.70 2.52 ± 0.90 0.943
HDL-C (mg/dL) 0.87 ± 0.23 0.85 ± 0.18 0.88 ± 0.25 0.314 0.92 ± 0.19 0.88 ± 0.24 0.509
TC (mg/dL) 4.03 ± 1.06 3.91 ± 1.0 4.07 ± 1.08 0.234 4.13 ± 0.97 4.0 ± 1.07 0.649
ALT (IU/L) 32.5 ± 13.6 29.5 ± 11.6 33.6 ± 15.3 0.206 24.5 ± 6.6 32.6 ± 17.8 0.222
AST (IU/L) 36.9 ± 15.5 39.2 ± 16.5 35.9 ± 12.9 0.622 27.5 ± 13.7 37.1 ± 21.9 0.478
Creatinine (μmol/L) 72.1 ± 17.9 71.7 ± 20.5 72.3 ± 16.8 0.778 78.4 ± 23.5 71.9 ± 17.4 0.134
UA (μmol/ L) 325.0 ± 58.8 323.4 ± 57.5 325.6 ± 59.5 0.831 356.5 ± 58.1 325.2 ± 46.5 0.148
BG (mmol/L) 6.49 ± 2.86 6.37 ± 2.47 6.53 ± 3.01 0.655 5.98 ± 1.98 6.5 ± 2.92 0.483
Clinical presentation, n (%)
 Unstable angina 181 (51.6) 54 (53.5) 127 (50.8) 0.651 9 (50) 172 (51.7) 0.891
 STEMI 114 (32.5) 35 (34.7) 79 (31.6) 0.58 4 (22.2) 110 (33.0) 0.443
 NSTEMI 56 (16.0) 26 (25.7) 30 (12.0) 0.001* 3 (16.7) 53 (15.9) 1.0
Final treatment, n (%)        
 PCI 276 (78.6) 80 (79.2) 196 (78.4) 0.867 8 (44.4) 268 (80.5) 0.001*
 CABG 5 (1.4) / 5 (2.0) 0.327 2 (11.1) 3 (0.9) 0.023*
 Medical treatment only 70 (19.9) 21 (20.8) 49 (19.6) 0.8 8 (44.4) 62 (18.6) 0.008*
Comorbidities, n%
 Hypertension 197 (56.1) 57 (56.4) 140 (56.0) 0.941 9 (50) 190 (57.1) 0.556
 Fatty liver 109 (31.1) 32 (31.7) 77 (30.8) 0.871 3 (16.7) 106 (31.8) 0.203
 Diabetes mellitus 138 (39.3) 39 (38.6) 99 (39.6) 0.864 7 (38.9) 131 (39.3) 1.0
 Dyslipidemia 272 (77.5) 77 (76.2) 195 (78) 0.72 13 (72.2) 259 (77.8) 0.583
History, n (%)        
 Previous MI 77 (21.9) 22 (21.8) 55 (22.0) 0.964 2 (11.1) 75 (22.5) 0.382
 Previous PCI 44 (12.50) 14 (13.9) 30 (12.0) 0.634 1 (5.6) 43 (12.9) 0.712
 Previous CABG 5 (1.4) 1 (1.0) 4 (1.6) 1.0 / 5 (2.1) 1.0
Concomitant medication, n%
 Statin 339 (96.6) 99 (98.0) 240 (96.0) 0.521 18 (100) 321 (96.4) 1.0
 PPI 158 (45.0) 46 (45.5) 112 (44.8) 0.899 9 (50) 149 (44.7) 0.662
 CCB 85 (24.2) 24 (23.8) 61 (24.4) 0.9 6 (33.3) 79 (23.7) 0.354
 β-Blocker 287 (81.8) 88 (87.1) 199 (79.6) 0.098 12 (66.7) 275 (82.6) 0.088
 Diuretics 92 (26.2) 32 (31.7) 60 (24.0) 0.138 5 (27.8) 87 (26.1) 0.877
 ARB or ACEI 266 (75.8) 73 (72.3) 193 (77.2) 0.330 10 (55.6) 257 (77.2) 0.036*
  1. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglycerides, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TC total cholesterol, ALT glutamic-pyruvic transaminase, AST glutamic-oxalacetic transaminase, UA uric acid, BG blood glucose, NSTEMI non-ST-segment elevation myocardial infarction, STEMI ST-segment elevation myocardial infarction, MACE major adverse cardiac events, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, ARB angiotensin receptor blocker, ACEI angiotensin antagonist inhibitor, CCB calcium channel blocker, PPI proton pump inhibitor
  2. *P < 0.05,* the difference of MACE vs. No-MACE or Bleeding vs. No-Bleeding group by χ2 test at 0.05